Amgen has unveiled plans for a $900 million expansion of its biotech manufacturing facility in Ohio, increasing its overall investment in the region to over $1.4 billion. This move is set to create 750 new jobs, further supporting the local economy, according to Reuters.
The expansion comes as part of a broader industry trend where major pharmaceutical companies like Eli Lilly, Novartis, Roche, and Johnson & Johnson are boosting U.S. manufacturing capabilities. These shifts are largely driven by potential import tariffs aimed at encouraging domestic production. Establishing new production facilities in the U.S. entails substantial investment and regulatory challenges, often requiring five to ten years and around $2 billion.
Since the 2017 Tax Cuts and Jobs Act, Amgen has committed nearly $5 billion to U.S. capital projects, contributing an estimated $12 billion to the nation's economy. Beyond Ohio, Amgen operates manufacturing sites in Massachusetts, Rhode Island, California, and around the globe, including Puerto Rico, Ireland, the Netherlands, and Singapore.
